NanoVibronix Inc (NASDAQ: NAOV) announced on Monday the successful completion of the pilot phase of a randomised controlled trial for UroShield, conducted by researchers at the University of Michigan.

This initial phase focused on nursing home residents and evaluated UroShield's ability to enhance patient quality of life by reducing urinary tract infections, catheter blockages and pain linked to long-term catheter use.

The study is set to progress to a full trial in 2025, building on the outcomes of the pilot phase.

UroShield employs NanoVibronix's patented low-intensity Surface Acoustic Wave (SAW) technology, designed to disrupt biofilms, reduce bacterial colonisation and alleviate pain.

Headquartered in Tyler, Texas, with R&D operations in Nesher, Israel, NanoVibronix specialises in portable therapeutic devices, including PainShield and WoundShield, which enable treatment without continuous medical supervision.